Background: Previous studies have reported that reduced mortality rates in hemodialysis (HD) patients were negatively related to body mass index (BMI). The potentially protective effect of increased BMI in HD patients has been referred to as ‘reverse epidemiology’. Our meta-analysis was conducted to examine the relationship between different BMI ranges and mortality in HD patients. Methods: Eligible studies assessing the effects of BMI ranges on all-cause mortality (published from 1966 to February 2012) were searched, using ‘hemodialysis’ or ‘haemodialysis’ and ‘obese’ or ‘body mass index’ or ‘overweight’ as key words, in combination with ‘mortality’, ‘survival’, ‘reverse epidemiology’ and ‘obesity paradox’. Inclusion criteria were that trials reported mortality in HD patients according to the traditional World Health Organization/National Institutes of Health BMI classification, and BMI levels are acceptable within 2 index points. The quality of the trials was evaluated using the risk of bias assessment in studies included in Cochrane reviews. The mortality rates in HD patients were the primary end point of the study. With no significant heterogeneity, a fixed-effects model was used for analyses. Results: Four studies with a total of 81,423 patients met final inclusion criteria. Compared to individuals with non-elevated BMI, those with elevated BMI (BMI ≥25, OR 0.67, 95% CI 0.65–0.68) had a lower all-cause mortality. In a risk-adjusted sensitivity analysis, elevated BMI levels (adjusted hazard ratio 0.94, 95% CI 0.92–0.96) remained protective against mortality. Conclusion: High BMI levels were associated with lower all-cause mortality rates in HD patients. It is possible that more stable hemodynamic status, cytokine and neurohormonal alternations contribute to the protective effects of BMI on mortality in HD patients. There is a need for prospective studies to elucidate mechanisms behind this relationship.

Keywords:
Systematic review, Body mass index, Mortality, Hemodialysis, Meta-analysis
1.
Arcan C, Hannan PJ, Himes JH, et al: American Indian parents’ assessment of and concern about their kindergarten child’s weight status. South Dakota, 2005–2006. Prev Chronic Dis 2012;9:E56.
2.
Wang Y, Chen X, Song Y, et al: Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008;73:19–33.
3.
Johansen KL, Kutner AG, Young B, et al: Association of body size with health status in patients beginning dialysis. Am J Clin Nutr 2006;83:543–549.
4.
de Mutsert R, Snijder MB, van der Sman-de Beer F, et al: Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol 2007;18:967–974.
5.
Yen TH, Lin JL, Lin-Tan DT, Hsu CW: Association between body mass and mortality in maintenance hemodialysis patients. Ther Apher Dial 2010;14:400–408.
6.
Physical status: the use and interpretation of anthropometry: report of a WHO Expert Committee. World Health Organization 1995;854:1–452.
7.
Kalantar-Zadeh K, Block G, Horwich T, et al: Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004;43:1439–1444.
8.
Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.6 (Updated March 2012). The Cochrane Collaboration, 2012. www.cochrane-handbook.org.
9.
Hoogeveen EK, Halbesma N, Rothman KJ, et al: Obesity and mortality risk among younger dialysis patients. Clin J Am Soc Nephrol 2012;7:1–9.
10.
Leavey SF, McCullough K, Hecking E, et al: Body mass index and mortality in ‘healthier’ as compared with ‘sicker’ haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001;16:2384–2394.
11.
Beddhu S, Pappas LM, Ramkumar N, Samore M: Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 2003;14:2366–2372.
12.
Kalantar-Zadeh K, Streja E, Kovesdy CP, et al: The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc 2010;85:991–1001.
13.
Ricks J, Molnar MZ, Kovesdy CP, et al: Racial and ethnic differences in the association of body mass index and survival in maintenance hemodialysis patients. Am J Kidney Dis 2011;58:574–582.
14.
Johansen KL, Young B, Kaysen GA, et al: Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr 2004;80:324–332.
15.
Kalantar-Zadeh K, Kilpartrick RD, Kuwae N, et al: Reverse epidemiology: a spurious hypothesis or a hardcore reality? Blood Purif 2005;23:57–63.
16.
Ness A, Gunnell D, Hughes J, et al: Height, body mass index, and survival in men with coronary disease: follow up of the Diet and Reinfarction Trial (DART). J Epidemiol Community Health 2002;56:218–219.
17.
Antigone O, Raj P, Kalantar-Zadeh K, et al: Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 2008;156:13–22.
18.
Ghali JK, Tam SW, Ferdinand KC, et al: Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial. Am J Cardiovasc Drugs 2007;7:373–380.
19.
Eqorova EN, Kalinkin MN, Mazur ES: Endotoxinemia and systemic inflammation in pathogenesis of chronic heart failure. Patol Fiziol Eksp Ter 2011;4:42–46.
20.
Kalantar-Zadeh K, Kopple JD, Humphreys MH, et al: Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 2004;19:1507–1519.
21.
Kalantar-Zadeh K, Kamranpour N, Kopple JD: Association between novel HDL inflammation/anti-inflammation properties with body mass index in hemodialysis patients. J Am Soc Nephrol 2004;15(suppl):172A.
22.
Fitzqibbons TP, Hardy OT, Lessard D, et al: Body mass index, treatment practices, and mortality in patients with acute heart failure. Coron Artery Dis 2009;20:536–543.
23.
Agarwal R: Body mass index-mortality paradox in hemodialysis: can it be explained by blood pressure? Hypertension 2011;58:1014–1020.
24.
Eqan M, Tannahill C, Petticrew M, et al: Psychosocial risk factors in home and community settings and their associations with population health and health inequalities: a systematic meta-review. BMC Public Health 2008;8:239.
25.
Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87–91.
26.
Atlantis E, Martin SA, Haren MT, et al: Inverse associations between muscle mass, strength, and the metabolic syndrome. Metabolism 2009;58:1013–1022.
27.
Ikizler TA, Wingard RL, Harvell J, et al: Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 1999;55:1945–1951.
28.
Honda H, Qureshi AR, Axelsson J, et al: Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr 2007;86:633–638.
29.
Huang CX, Tighiouart H, Beddhu S, et al: Both low muscle mass and low fat are associated with higher all-cause mortality in hemodialysis patients. Kidney Int 2010;77:624–629.
30.
Gotch FA: Kt/V is the best dialysis dose parameter. Blood Purif 2000;18:276–285.
31.
Horber FF, Kohler SA, Lippuner K, et al: Effect of regular physical training on age-associated alteration of body composition in men. Eur J Clin Invest 1996;26:279–285.
32.
Mustata S, Chan C, Lai V, et al: Impact of an exercise program on arterial stiffness and insulin resistance in hemodialysis patients. J Am Soc Nephrol 2004;15:2713–2718.
33.
Shoji T, Emoto M, Shinohara K, et al: Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001;12:2117–2124.
34.
Shinohara K, Shoji T, Emoto M, et al: Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002;13:1894–1900.
35.
Cordeiro AC, Qureshi AR, Stenvinkel P, et al: Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant 2010;25:562–568.
36.
Pischon T, Boeing H, Hoffmann K, et al: General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008;359:2105–2120.
37.
Postorino M, Marino C, Tripepi G, et al: Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease. J Am Coll Cardiol 2009;53:1265–1272.
38.
Axelsson J, Rashid Qureshi A, Suliman ME, et al: Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004;80:1222–1229.
39.
Gohda T, Gotoh H, Tanimoto M, et al: Relationship between abdominal fat accumulation and insulin resistance in hemodialysis patients. Hypertens Res 2008;31:83–88.
40.
Odamaki M, Furuya R, Kinumura Y, et al: Association between plasma adiponectin concentration and visceral fat accumulation in hemodialysis patients. Nephron Clin Pract 2006;102:c8–c13.
41.
Ramos LF, Shintani A, Ikizler TA, et al: Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 2008;19:593–599.
42.
Fouque D, Kalantar-Zadeh K, Kopple J, et al: A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008;73:391–398.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.